Everyone knows that exercise is good for both people with and without cancer, including advanced prostate cancer. For us advanced prostate cancer survivors, going on and off therapy probably makes exercise evn more important than for the general population. It is well known that people with stronger, leaner bodies have more energy, are healthier and [...]
Sipuleucel-T (Provenge) is FDA approved after a man becomes castrate resistant. In clinical trials it has shown that it extends life when compared to placebo. The use of Provenge has raised many questions, the two most common ones are why PSA and disease progression continues while receiving this treatment (see post at for an explanation) [...]
There are now two new, additional sites added to the Early Access Trial of the investigational treatment known as Radium-233 or Alpharadin for men with castrate resistant prostate cancer with multiple bone metastases. This post contains the most up to date and accurate information, the clinical trials.gov site is NOT currently accurate. Additionally, there are [...]
We won't let you fight your prostate cancer alone. Our mission is simple. We are men, fighting cancer, together. We share lifesaving information about the newest treatments, best (and worst) doctors and clinical trial admissions. Our Advanced Prostate Cancer program, run by Joel, has helped several thousand men live longer and happier lives in the [...]
Researchers at the Harvard Medical School investigated the effect of androgen deprivation in a preclinical mouse model of stable high grade prostatic intraepithelial neoplasia induced by the loss of the PTEN tumor suppressor. They found that androgen deprivation treatment of these mice accelerated the progression to invasive disease. Shidong Jia, M.D., Ph.D. And associates found [...]
A comprehensive study of prostate cancer tissue done in the UK has revealed that a completely new gene network takes over driving the cancer in men who are castrate resistant. The research was published in Cancer Cell. Researchers at the Cancer Research UK Cambridge Research Institute, at the University of Cambridge studied tissue samples from [...]
Mortality prospects after a prostate cancer recurrences following a radical prostatectomy has always been assumed to be directly related to the early development of metastases. A study from Melbourne Australia indicates that men with low-risk prostate cancer have good mortality prospects even when they experience early biochemical recurrence. The first author of the study, Anthony [...]
There has been much discussion about the timing of treatments now that we have new drugs available to treat advanced prostate cancer. However, today’s technology does not allow us to know what the best sequencing of these drugs to maximize their efficacy would be, so we just punt along. We do not know whether or [...]
On Thursday evening I had the opportunity to meet Dr. Oliver Sartor from the University of Tulane. At that time he informed me that Bayer had finally submitted the required paperwork to the FDA for formal approval of radium-233 chloride. For those of you who are not familiar with Dr. Sartor, he is both an [...]
According to researchers from the University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan men with advanced prostate cancer experienced significant and rapid positive effects from an investigational treatment known as cabozantinib. In a n article published online in the Journal of Clinical Oncology (Nov. 19, 2012) approximately two-thirds of men who were treated with [...]
